| Product NDC: | 10019-925 |
| Proprietary Name: | IFOSFAMIDE |
| Non Proprietary Name: | IFOSFAMIDE |
| Active Ingredient(s): | 1 g/20mL & nbsp; IFOSFAMIDE |
| Administration Route(s): | INTRAVENOUS |
| Dosage Form(s): | INJECTION, POWDER, FOR SOLUTION |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 10019-925 |
| Labeler Name: | Baxter Healthcare Corporation |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA019763 |
| Marketing Category: | NDA |
| Start Marketing Date: | 19881230 |
| Package NDC: | 10019-925-01 |
| Package Description: | 1 VIAL, SINGLE-DOSE in 1 CARTON (10019-925-01) > 20 mL in 1 VIAL, SINGLE-DOSE (10019-925-82) |
| NDC Code | 10019-925-01 |
| Proprietary Name | IFOSFAMIDE |
| Package Description | 1 VIAL, SINGLE-DOSE in 1 CARTON (10019-925-01) > 20 mL in 1 VIAL, SINGLE-DOSE (10019-925-82) |
| Product NDC | 10019-925 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | IFOSFAMIDE |
| Dosage Form Name | INJECTION, POWDER, FOR SOLUTION |
| Route Name | INTRAVENOUS |
| Start Marketing Date | 19881230 |
| Marketing Category Name | NDA |
| Labeler Name | Baxter Healthcare Corporation |
| Substance Name | IFOSFAMIDE |
| Strength Number | 1 |
| Strength Unit | g/20mL |
| Pharmaceutical Classes | Alkylating Activity [MoA],Alkylating Drug [EPC] |